RxDoctor Payments Data

Robert Steele, PA

Medical · Myrtle, MSNPI 1053887208

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 8 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $106 and has fallen 55.4% since, to $47 in 2025. That places this record below the midpoint for medical clinicians in MS, where the typical reported total is $1,097.

$287in general payments, 2019–2025

Across 16 payments — averaging $17.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$62
  • AbbVie$58
  • Takeda Pharmaceuticals U.S.A., Inc.$44
  • Pfizer$38
  • Supernus Pharmaceuticals, Inc.$36
  • Novo Nordisk$22
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$287100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$287 in reported general payments places this provider in the 25th percentile of 65 medical providers in Mississippi.

See all medical providers in Mississippi

Medicare billing

Part B allowed, 2024
$41,186
Medicare patients
292
Services billed
1,049

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide32$42,495
JardianceEmpagliflozin19$20,871
TradjentaLinagliptin12$18,464
LinzessLinaclotide16$17,424
MounjaroTirzepatide15$14,024
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$12,761
Lurasidone Hcl11$3,342
ShingrixVaricella-Zoster Ge/As01b/Pf12$2,514
Gabapentin84$1,152
Albuterol Sulfate HfaAlbuterol Sulfate33$1,048
Omeprazole96$965
Metoprolol Succinate34$740
Diclofenac Sodium28$666
Methocarbamol33$478
Chlorthalidone29$449

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$22$42,49532 claims
AbbVieLinzess$58$17,42416 claims
GSKTrelegy Ellipta, Shingrix$14$15,27529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 65 medical providers in Mississippi.

Other medical in Myrtle

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →